Bachem Holding AG Stock Swiss Exchange
Equities
BANB
CH0012530207
Biotechnology & Medical Research
Sales 2024 * | 620M 684M | Sales 2025 * | 811M 894M | Capitalization | 6.25B 6.9B |
---|---|---|---|---|---|
Net income 2024 * | 127M 140M | Net income 2025 * | 160M 176M | EV / Sales 2024 * | 9.98 x |
Net cash position 2024 * | 64.89M 71.57M | Net Debt 2025 * | 74.85M 82.55M | EV / Sales 2025 * | 7.8 x |
P/E ratio 2024 * |
52
x | P/E ratio 2025 * |
39.4
x | Employees | 2,006 |
Yield 2024 * |
1.03% | Yield 2025 * |
1.12% | Free-Float | 94.31% |
Latest transcript on Bachem Holding AG
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 18-12-31 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 12-04-24 |
Director/Board Member | 51 | 11-04-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | +7.69% | - |
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |